scholarly journals Gadofluorine M enhanced MRI in experimental glioma: Superior and persistent intracellular tumor enhancement compared with conventional MRI

2011 ◽  
Vol 35 (3) ◽  
pp. 551-560
Author(s):  
Leonie Jestaedt ◽  
Dieter Lemke ◽  
Markus Weiler ◽  
Philipp-Niclas Pfenning ◽  
Sabine Heiland ◽  
...  
1997 ◽  
Vol 21 (6) ◽  
pp. 965-968 ◽  
Author(s):  
Khaled I. El-Noueam ◽  
Mark E. Schweitzer ◽  
Manoj Bhatia ◽  
Arthur R. Bartolozzi

2018 ◽  
Vol 60 (6) ◽  
pp. 777-787 ◽  
Author(s):  
Chun-Qiu Su ◽  
Shan-Shan Lu ◽  
Qiu-Yue Han ◽  
Mao-Dong Zhou ◽  
Xun-Ning Hong

Background The application of conventional magnetic resonance imaging (MRI) in glioma grading is limited and non-specific. Purpose To investigate the application values of MRI, texture analysis (TA) of dynamic contrast-enhanced MRI (DCE-MRI) and intratumoral susceptibility signal (ITSS) on susceptibility weighted imaging (SWI), alone and in combination, for glioma grading. Material and Methods Fifty-two patients with pathologically confirmed gliomas who underwent DCE-MRI and SWI were enrolled in this retrospective study. Conventional MRIs were evaluated by the VASARI scoring system. TA of DCE-MRI-derived parameters and the degree of ITSS were compared between low-grade gliomas (LGGs) and high-grade gliomas (HGGs). The diagnostic ability of each parameter and their combination for glioma grading were analyzed. Results Significant statistical differences in VASARI features were observed between LGGs and HGGs ( P < 0.05), of which the enhancement quality had the highest area under the curve (AUC) (0.873) with 93.3% sensitivity and 80% specificity. The TA of DCE-MRI derived parameters were significantly different between LGGs and HGGs ( P < 0.05), of which the uniformity of Ktrans had the highest AUC (0.917) with 93.3% sensitivity and 90% specificity. The degree of ITSS was significantly different between LGGs and HGGs ( P < 0.001). The AUC of the ITSS was 0.925 with 93.3% sensitivity and 90% specificity. The best discriminative power was obtained from a combination of enhancement quality, Ktrans- uniformity, and ITSS, resulting in 96.7% sensitivity, 100.0% specificity, and AUC of 0.993. Conclusion Combining conventional MRI, TA of DCE-MRI, and ITSS on SWI may help to improve the differentiation between LGGs and HGGs.


2009 ◽  
Vol 2 (5) ◽  
pp. 391-396 ◽  
Author(s):  
Marc Sirol ◽  
Pedro R. Moreno ◽  
K.-Raman Purushothaman ◽  
Esad Vucic ◽  
Vardan Amirbekian ◽  
...  

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 208-208
Author(s):  
Anna Mary Brown ◽  
Sandeep Sankineni ◽  
Marcelino Bernardo ◽  
Dagane Daar ◽  
Juanita Weaver ◽  
...  

208 Background: Conventional imaging methods of lymph node staging in prostate cancer are limited. The goal of this study is to determine the utility of ferumoxytol enhanced MRI in lymph node (LN) staging. Methods: This ongoing IRB-approved clinical trial enrolls prostate cancer patients at high risk for LN metastases. Patients first undergo baseline T2 and T2* weighted MRI scans followed by 7.5mg/Kg ferumoxytol injection. Repeat scans are acquired at 24 hr and 48 hr post-injection. The criterion for positive LNs was hyperintense signal indicating failure to take up ferumoxytol. Validation was determined on clinical grounds or by histopathology when available. Results: To date, 11 patients have completed the study. One patient was examined pre-operatively while the other 10 had suspected therapy failure. Median age and PSA were 65 yrs (36-75) and 5.6ng/dL (0.3-201). Of 16 LNs with median size 1.6 x 1.1cm, 10 were true positives, one was false positive and one was false negative with 4 nodes pending validation. The LN status was correctly identified in 8 of 11 patients [Table]. Conclusions: Ferumoxytol enhanced MRI shows promise in detecting malignant LNs with diameter >6mm in prostate cancer paients. This method is performed in a conventional MRI unit with off-label use of an FDA-approved agent and thus could be widely available. However, further validation is necessary before routine use. Clinical trial information: NCT02141490. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document